ArticleInternational journal for parasitology. Drugs and drug resistance2026
Halogenation of neolignan scaffolds reveals stage-specific anthelmintic activity against Haemonchus contortus.
Article in International journal for parasitology. Drugs and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal nematodes, including Haemonchus contortus, represent a major constraint to livestock production globally, and the increasing prevalence of anthelmintic resistance necessitates the discovery of new chemotypes. Natural products provide a rich and underexplored source of bioactive scaffolds for anthelmintic development. However, there remains a need to systematically optimise such scaffolds to define structure-activity relationships in whole-organism systems. Here, we investigated neolignan compounds from the fruits of Styrax suberifolius and assessed the impact of halogenation on their anthelmintic activity. Two known neolignans, suberifolioside A and equiselignan B, were isolated and used to generate a series of 11 halogenated derivatives using N-halosuccinimide chemistry. In addition, a new glycoside, suberifolioside B, together with two known metabolites, 7R,8S-dihydrodehydrodiconiferyl alcohol and 3',4-O-dimethylcedrusin, were characterised by spectroscopic and spectrometric methods, and the absolute configuration of equiselignan B was confirmed by X-ray crystallography. All compounds were evaluated for activity against larval stages of H. contortus using an established in vitro phenotypic assay. While no compounds significantly affected exsheathed third-stage larvae, multiple derivatives displayed activity against fourth-stage larvae, indicating pronounced stage-specific susceptibility. Notably, halogenation of the neolignan scaffold modulated biological activity, with several derivatives inducing substantial reductions in larval motility and distinct abnormal phenotypes. This modulation was non-linear, with both mono- and poly-halogenated derivatives displaying activity. A monobrominated ether analogue exhibited maximal motility inhibition approaching that observed for moxidectin under the assay conditions, highlighting the potential of this scaffold for optimisation. These findings demonstrate that halogenated neolignans represent a tractable chemical class for anthelmintic discovery and reveal stage-specific vulnerabilities in H. contortus. This work provides a foundation for further optimisation and prioritisation of neolignan derivatives for downstream studies of mechanism of action and translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.